Rogers Corporation (ROG)

76.74
NYSE
Prev Close 76.86
Day Low/High 75.76 / 77.00
52 Wk Low/High 41.92 / 77.14
Exchange NYSE
Shares Outstanding 17.97B
Market Cap 1.38B
Div & Yield N.A. (N.A)

Latest News

Genentech's Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared To Rituxan

Genentech's Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared To Rituxan

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced data from the positive, pivotal Phase III GALLIUM study that compared Gazyva ® (obinutuzumab) plus chemotherapy followed by Gazyva...

Rogers Acquires DeWAL Industries

Rogers Acquires DeWAL Industries

Rogers Corporation (NYSE:ROG), a global leader in engineered material solutions, announces the acquisition of DeWAL Industries, a leading manufacturer of high performance polymer films and pressure sensitive tapes.

Roche Launches DISCOVERY 5-Plex Procedure For Cancer Research Applications

Roche Launches DISCOVERY 5-Plex Procedure For Cancer Research Applications

Fully automated fluorescent multiplex procedure enables researchers to investigate up to five biomarkers on one tissue slide

ROG Crosses Above Average Analyst Target

ROG Crosses Above Average Analyst Target

In recent trading, shares of Rogers Corp. have crossed above the average analyst 12-month target price of $73.33, changing hands for $76.05/share.

Phase III GiACTA Study Shows Genentech's Actemra® Is Superior To Steroids Alone In Maintaining Steroid-Free Remission For People With Giant Cell Arteritis

Phase III GiACTA Study Shows Genentech's Actemra® Is Superior To Steroids Alone In Maintaining Steroid-Free Remission For People With Giant Cell Arteritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III GiACTA study, which evaluated Actemra ® (tocilizumab) in people with GCA.

Roche Launches New RNA HyperPrep Product Line

Roche Launches New RNA HyperPrep Product Line

A streamlined solution for the preparation of high-quality RNA-sequencing libraries

Genentech Showcases New Clinical Data Across A Variety Of Blood Diseases At American Society Of Hematology 2016 Annual Meeting

Genentech Showcases New Clinical Data Across A Variety Of Blood Diseases At American Society Of Hematology 2016 Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that more than 60 abstracts featuring nine of its approved or investigational medicines will be presented during the 58th American Society...

Rogers Corporation Reports Results For The 2016 Third Quarter

Rogers Corporation Reports Results For The 2016 Third Quarter

Rogers Corporation (NYSE:ROG) today announced financial results for the 2016 third quarter.

Genentech To Present New Data On Medicines For Autoimmune Diseases And Severe Inflammatory Disorders At The 2016 ACR/ARHP Annual Meeting

Genentech To Present New Data On Medicines For Autoimmune Diseases And Severe Inflammatory Disorders At The 2016 ACR/ARHP Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from Actemra ® (tocilizumab) and Rituxan ® (rituximab) will be presented during the 2016 American College of...

Roche Announces FDA Approval For VENTANA PD-L1 (SP142) Assay To Support Immunotherapy Treatment Decisions In Lung Cancer

Roche Announces FDA Approval For VENTANA PD-L1 (SP142) Assay To Support Immunotherapy Treatment Decisions In Lung Cancer

First FDA-approved test to support patient treatment decisions for TECENTRIQ (atezolizumab) in non-small cell lung cancer

Rogers Corporation Invites You To Join Its 2016 Third Quarter Earnings Conference Call

Rogers Corporation Invites You To Join Its 2016 Third Quarter Earnings Conference Call

Rogers Corporation (NYSE: ROG) plans to announce results for its 2016 third quarter after the close of trading on Wednesday, November 2, 2016.

LabCorp Is First US Laboratory To Offer Molecular Testing With New Fully Automated Cobas 8800 System From Roche

LabCorp Is First US Laboratory To Offer Molecular Testing With New Fully Automated Cobas 8800 System From Roche

First high-throughput molecular platform approved for CLIA moderately complex testing expected to enhance quality, streamline workflow and better utilize staff

Roche Receives FDA Approval For Fully Automated Blood Screening Assay On The Cobas® 6800/8800 Systems

Roche Receives FDA Approval For Fully Automated Blood Screening Assay On The Cobas® 6800/8800 Systems

Next generation cobas® MPX assay now approved for donor screening applications in the United States

Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916

Spinal Muscular Atrophy Program Advances Into Phase 2 Clinical Studies In SMA Patients With RG7916

- Initiated SUNFISH study to evaluate RG7916 in Type 2/3 SMA patients -

FDA Approves Genentech's Cancer Immunotherapy TECENTRIQ® (Atezolizumab) For People With A Specific Type Of Metastatic Lung Cancer

FDA Approves Genentech's Cancer Immunotherapy TECENTRIQ® (Atezolizumab) For People With A Specific Type Of Metastatic Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Approves Genentech's Lucentis® (Ranibizumab Injection) Prefilled Syringe

FDA Approves Genentech's Lucentis® (Ranibizumab Injection) Prefilled Syringe

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Grants Priority Review To Genentech's Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application For Myopic Choroidal Neovascularization

FDA Grants Priority Review To Genentech's Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application For Myopic Choroidal Neovascularization

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech's TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared To Chemotherapy Regardless Of PD-L1 Status In A Specific Type Of Lung Cancer In Phase III Study

Genentech's TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared To Chemotherapy Regardless Of PD-L1 Status In A Specific Type Of Lung Cancer In Phase III Study

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced data from the positive, pivotal Phase III OAK study of TECENTRIQ ® (atezolizumab) at the European Society of Medical Oncology (ESMO)...

FDA Grants Breakthrough Therapy Designation For Genentech's Actemra® (Tocilizumab) In Giant Cell Arteritis, A Form Of Vasculitis

FDA Grants Breakthrough Therapy Designation For Genentech's Actemra® (Tocilizumab) In Giant Cell Arteritis, A Form Of Vasculitis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

FDA Grants Breakthrough Therapy Designation For Genentech's Alecensa® (Alectinib) For First-Line Treatment Of People With ALK-Positive NSCLC

FDA Grants Breakthrough Therapy Designation For Genentech's Alecensa® (Alectinib) For First-Line Treatment Of People With ALK-Positive NSCLC

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it has received a second Breakthrough Therapy Designation (BTD) from the U.

Harmony® Prenatal Test For Assessment Of Down Syndrome And Other Chromosomal Disorders Receives CE Mark

Harmony® Prenatal Test For Assessment Of Down Syndrome And Other Chromosomal Disorders Receives CE Mark

Laboratories, healthcare providers, and expectant parents receive greater access to the non-invasive prenatal test

FDA Grants Roche Label Extension For The Cobas® EGFR Mutation Test V2 For Use With Plasma As A Companion Diagnostic For TAGRISSO™

FDA Grants Roche Label Extension For The Cobas® EGFR Mutation Test V2 For Use With Plasma As A Companion Diagnostic For TAGRISSO™

Test utilizes either plasma or tumor tissue, as a companion diagnostic for non-small cell lung cancer therapies

Phase III Efficacy Results Of Investigational Medicine OCREVUS™ (Ocrelizumab) Reinforced By Exploratory Analyses In Two Forms Of Multiple Sclerosis

Phase III Efficacy Results Of Investigational Medicine OCREVUS™ (Ocrelizumab) Reinforced By Exploratory Analyses In Two Forms Of Multiple Sclerosis

Genentech, a member of the Roche group (SIX: RO, ROG; OTCQX: RHHBY), today announced new analyses from the three OCREVUS™ (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive...

Phase III Study Showed Genentech's Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Helped People With A Specific Type Of Lung Cancer Live Significantly Longer Compared To Chemotherapy

Phase III Study Showed Genentech's Cancer Immunotherapy TECENTRIQ™ (Atezolizumab) Helped People With A Specific Type Of Lung Cancer Live Significantly Longer Compared To Chemotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results for TECENTRIQ from the Phase III study, OAK.